Richard Pazdur

72PUBLICATIONS
312CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyMolecular targetsMedical biotechnology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (72)

|Mar 06, 2026
FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer.

Sandra J Casak, Yiming Zhang, Chi Song

|Feb 12, 2026
FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle-Invasive Bladder Cancer.

Nooshin Mirkheshti, Daniel Edem Kpormegbey, Chana Weinstock

|Jan 26, 2026
FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer.

Yufan Liu, Jeannette Nashed, Amy K Barone

|Oct 24, 2025
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.

Nina Kim, E Dianne Pulte, Lori A Ehrlich

|Sep 05, 2025
FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.

Michael I Barbato, Amy K Barone, Stephanie L Aungst

|Aug 27, 2025
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.

Melanie Royce, Mirat Shah, Lijun Zhang

Pageof 12

Frequent Collaborators

28 joint publications

Laleh Amiri-Kordestani

28 joint publications

Shenghui Tang

24 joint publications

Paul Kluetz

19 joint publications

William Pierce